Expert Insights

C. Ola Landgren, MD, PhD shares updates on improvements in cancer outcomes, including prolonged survival and tolerability, for patients with newly diagnosed multiple myeloma who are transplant-ineligible.

Matthew Powell, MD, discusses results from the KEYLINK-001 study which demonstrated that the addition of pembrolizumab and olaparib to standard therapy improved progression-free survival among patients with advanced BRCA non-mutated...

Allison Brodsky, MD, discusses translational results from the phase 1b COPANIRA trial which assessed the relationship between molecular profiling and response to copanlisib and niraparib among patients with recurrent ovarian and endometrial...

Dr Van Gorp shares insights on the final analysis of the MIRASOL trial evaluating mirvetuximab soravtansine among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer.

Michael Green, PhD, discusses relapsed/refractory diffuse large B-cell lymphoma microenvironment archetypes and the effect of immunomodulatory and cellular therapies on patient outcomes.

Lori Wirth, MD, discusses the selpercatinib for advanced RET-mutant medullary thyroid cancer and RET fusion-positive, radioactive iodine-refractory differentiated thyroid cancer.

Mira Milas, MD, and Christian Nasr, MD, discuss the potential of neoadjuvant tyrosine kinase inhibition to downstage unresectable differentiated thyroid cancer.

Mira Milas, MD, and Christian Nasr, MD, discuss the potential of neoadjuvant tyrosine kinase inhibition to downstage unresectable differentiated thyroid cancer.

Laurence Albiges, MD, PhD, discusses the final results from the COSMIC-313 trial which evaluated cabozantinib plus nivolumab and ipilimumab for patients with previously untreated advanced renal cell carcinoma.

Laura Dawson, MD, discusses the results of a phase 3 study comparing stereotactic body radiotherapy followed by sorafenib to sorafenib alone for patients with locally advanced hepatocellular carcinoma.